Nifty
:
23431.50
Sensex
:
74764.23
-203.60 (-0.86%)
-813.35 (-1.08%)
Nifty
Sensex
:
:
23431.50
74764.23
-203.60 (-0.86%)
-813.35 (-1.08%)

Kwality Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

Rating :
84/99

BSE: 539997 | NSE: KPL

NSE BSE
3577.00
09-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  3678.9
  •  3798.9
  •  3552.5
  •  3661.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  42952
  •  156845032.9
  •  3798.9
  •  1561

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,714.52
  • 45.83
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,841.39
  • N/A
  • 10.42

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.86%
  • 1.34%
  • 31.03%
  • FII
  • DII
  • Others
  • 3.13%
  • 0.00%
  • 9.64%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.73
  • 1.98
  • 17.87

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 29.55
  • -7.19
  • 12.26

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 34.92
  • -10.91
  • 41.44

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.58
  • 26.93
  • 29.17

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.38
  • 4.69
  • 3.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.14
  • 11.93
  • 12.92

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
162.35
111.48
45.63%
157.11
115.68
35.81%
123.44
84.41
46.24%
111.05
90.03
23.35%
Expenses
121.33
87.30
38.98%
118.35
89.79
31.81%
93.49
66.91
39.73%
85.70
70.37
21.78%
EBITDA
41.02
24.18
69.64%
38.76
25.89
49.71%
29.95
17.50
71.14%
25.35
19.66
28.94%
EBIDTM
25.27%
21.69%
24.67%
22.38%
24.26%
20.73%
22.83%
21.84%
Other Income
0.62
0.38
63.16%
1.06
0.77
37.66%
0.53
0.66
-19.70%
0.90
0.22
309.09%
Interest
2.66
2.76
-3.62%
2.89
2.49
16.06%
2.48
2.20
12.73%
2.84
2.71
4.80%
Depreciation
5.00
4.76
5.04%
5.26
5.09
3.34%
4.82
4.56
5.70%
4.96
4.62
7.36%
PBT
33.99
17.03
99.59%
31.67
19.07
66.07%
22.34
11.39
96.14%
18.45
12.55
47.01%
Tax
8.37
5.11
63.80%
6.36
4.59
38.56%
6.35
2.87
121.25%
4.34
4.10
5.85%
PAT
25.62
11.92
114.93%
25.31
14.48
74.79%
16.00
8.52
87.79%
14.11
8.46
66.78%
PATM
15.78%
10.69%
16.11%
12.52%
12.96%
10.10%
12.71%
9.39%
EPS
24.70
11.49
114.97%
24.38
13.96
74.64%
15.43
8.22
87.71%
13.60
8.16
66.67%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
553.95
503.08
370.20
307.17
251.03
456.19
262.01
139.30
166.29
137.49
98.32
Net Sales Growth
37.94%
35.89%
20.52%
22.36%
-44.97%
74.11%
88.09%
-16.23%
20.95%
39.84%
 
Cost Of Goods Sold
287.82
179.44
116.19
89.63
69.44
141.83
165.59
87.08
119.44
101.59
71.29
Gross Profit
266.13
323.64
254.00
217.55
181.59
314.36
96.42
52.22
46.85
35.91
27.03
GP Margin
48.04%
64.33%
68.61%
70.82%
72.34%
68.91%
36.80%
37.49%
28.17%
26.12%
27.49%
Total Expenditure
418.87
384.84
289.81
240.86
190.30
284.52
233.16
125.10
150.59
125.82
89.44
Power & Fuel Cost
-
26.69
23.37
17.23
12.98
11.07
6.13
4.20
3.71
2.71
2.81
% Of Sales
-
5.31%
6.31%
5.61%
5.17%
2.43%
2.34%
3.02%
2.23%
1.97%
2.86%
Employee Cost
-
51.10
41.26
30.46
28.16
18.80
14.70
10.92
7.74
4.89
3.60
% Of Sales
-
10.16%
11.15%
9.92%
11.22%
4.12%
5.61%
7.84%
4.65%
3.56%
3.66%
Manufacturing Exp.
-
81.84
71.16
75.33
50.12
68.38
7.02
3.54
2.87
5.16
2.64
% Of Sales
-
16.27%
19.22%
24.52%
19.97%
14.99%
2.68%
2.54%
1.73%
3.75%
2.69%
General & Admin Exp.
-
23.95
18.07
17.66
16.11
10.95
12.85
8.48
5.83
3.19
2.61
% Of Sales
-
4.76%
4.88%
5.75%
6.42%
2.40%
4.90%
6.09%
3.51%
2.32%
2.65%
Selling & Distn. Exp.
-
21.04
18.22
8.71
12.66
33.27
25.90
10.60
10.79
8.07
5.04
% Of Sales
-
4.18%
4.92%
2.84%
5.04%
7.29%
9.89%
7.61%
6.49%
5.87%
5.13%
Miscellaneous Exp.
-
0.79
1.52
1.83
0.83
0.23
0.97
0.28
0.19
0.23
5.04
% Of Sales
-
0.16%
0.41%
0.60%
0.33%
0.05%
0.37%
0.20%
0.11%
0.17%
1.48%
EBITDA
135.08
118.24
80.39
66.31
60.73
171.67
28.85
14.20
15.70
11.67
8.88
EBITDA Margin
24.38%
23.50%
21.72%
21.59%
24.19%
37.63%
11.01%
10.19%
9.44%
8.49%
9.03%
Other Income
3.11
2.86
1.92
1.83
2.94
3.51
1.59
3.66
0.61
0.80
1.21
Interest
10.87
10.97
9.88
10.39
6.61
2.92
2.68
2.50
2.28
2.20
1.93
Depreciation
20.04
19.81
18.29
19.56
14.96
10.69
6.49
4.43
3.12
2.98
2.51
PBT
106.45
90.32
54.14
38.20
42.10
161.57
21.27
10.92
10.91
7.30
5.65
Tax
25.42
22.15
14.34
7.48
6.29
41.63
6.38
2.71
3.35
2.87
2.37
Tax Rate
23.88%
24.75%
26.49%
24.05%
24.60%
25.77%
30.00%
24.82%
30.71%
39.32%
41.95%
PAT
81.04
67.35
39.84
23.80
19.37
119.99
15.15
8.32
7.56
4.54
3.37
PAT before Minority Interest
81.04
67.35
39.80
23.62
19.28
119.94
14.89
8.21
7.56
4.42
3.28
Minority Interest
0.00
0.00
0.04
0.18
0.09
0.05
0.26
0.11
0.00
0.12
0.09
PAT Margin
14.63%
13.39%
10.76%
7.75%
7.72%
26.30%
5.78%
5.97%
4.55%
3.30%
3.43%
PAT Growth
86.81%
69.05%
67.39%
22.87%
-83.86%
692.01%
82.09%
10.05%
66.52%
34.72%
 
EPS
77.92
64.76
38.31
22.88
18.63
115.38
14.57
8.00
7.27
4.37
3.24

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
331.60
264.05
224.21
200.52
181.14
61.15
46.01
37.30
29.75
25.58
Share Capital
10.38
10.38
10.38
10.38
10.38
10.38
10.38
10.38
10.38
5.19
Total Reserves
321.22
253.67
213.84
190.14
170.77
50.78
35.63
26.92
19.37
20.40
Non-Current Liabilities
34.27
13.76
19.75
28.62
21.32
28.08
19.78
8.23
5.47
4.24
Secured Loans
29.40
15.12
19.56
27.19
19.59
16.26
8.18
7.01
3.11
2.63
Unsecured Loans
0.00
0.00
0.00
0.12
0.70
2.00
2.00
0.58
1.59
0.67
Long Term Provisions
1.18
0.25
0.22
0.90
0.75
0.68
0.62
0.52
0.55
0.54
Current Liabilities
225.52
169.50
151.85
125.95
139.49
78.29
67.75
60.83
61.98
41.60
Trade Payables
101.69
55.79
44.32
35.19
34.51
26.21
22.97
17.07
22.14
12.74
Other Current Liabilities
29.78
24.28
34.91
33.31
40.97
29.82
20.55
21.73
15.91
11.46
Short Term Borrowings
85.46
83.33
66.02
50.96
23.00
16.45
21.24
18.73
21.33
15.09
Short Term Provisions
8.59
6.10
6.60
6.48
41.00
5.80
3.00
3.30
2.60
2.30
Total Liabilities
589.72
445.66
394.18
353.64
340.60
166.22
132.50
105.38
96.21
70.92
Net Block
155.57
145.69
139.05
120.50
91.73
56.53
42.69
22.60
16.48
15.65
Gross Block
261.26
231.57
206.64
170.15
128.13
82.22
62.60
41.16
31.92
28.22
Accumulated Depreciation
105.68
85.87
67.58
49.65
36.39
25.69
19.91
18.56
15.44
12.56
Non Current Assets
184.03
161.88
151.49
146.43
112.77
60.33
43.46
29.99
21.14
17.75
Capital Work in Progress
17.01
0.00
0.00
14.29
12.15
2.89
0.00
6.48
3.90
1.36
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.73
0.65
0.79
0.63
0.62
Long Term Loans & Adv.
11.45
16.19
12.44
10.71
8.11
0.17
0.12
0.12
0.12
0.12
Other Non Current Assets
0.00
0.00
0.00
0.93
0.78
0.00
0.00
0.00
0.00
0.00
Current Assets
405.68
283.78
242.69
207.20
227.82
105.90
89.03
75.35
75.00
53.07
Current Investments
0.00
0.00
0.00
0.00
0.00
4.44
3.34
4.04
4.71
3.03
Inventories
78.25
83.47
78.39
86.31
53.36
17.36
22.42
11.25
15.03
13.85
Sundry Debtors
280.05
154.31
114.39
71.69
69.13
35.71
30.33
38.43
37.03
22.61
Cash & Bank
3.59
14.76
5.94
7.36
12.95
5.81
1.54
1.40
1.61
2.99
Other Current Assets
43.78
0.00
7.03
0.00
92.38
42.58
31.41
20.24
16.61
10.58
Short Term Loans & Adv.
43.48
31.25
36.94
41.83
92.38
42.49
31.29
20.18
16.49
10.53
Net Current Assets
180.16
114.27
90.84
81.25
88.33
27.61
21.28
14.52
13.02
11.47
Total Assets
589.71
445.66
394.18
353.63
340.59
166.23
132.49
105.37
96.21
70.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
16.59
52.72
42.98
41.38
60.60
26.71
6.16
13.58
-0.57
4.30
PBT
89.49
54.14
31.10
25.57
161.57
21.27
10.92
10.91
7.30
5.65
Adjustment
31.27
28.00
36.62
20.95
13.56
9.09
7.09
5.22
4.36
4.69
Changes in Working Capital
-83.40
-13.64
-23.44
1.01
-73.18
2.72
-9.13
0.89
-9.17
-3.62
Cash after chg. in Working capital
37.35
68.51
44.28
47.54
101.95
33.09
8.87
17.02
2.49
6.72
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-20.77
-15.79
-1.30
-6.16
-41.35
-6.38
-2.71
-3.44
-3.06
-2.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-34.91
-28.52
-26.40
-48.44
-62.93
-23.20
-17.80
-11.78
-6.20
-7.26
Net Fixed Assets
-46.70
-24.54
-22.20
-44.16
-55.17
-22.50
-14.92
-11.81
-6.25
-6.79
Net Investments
0.00
0.00
0.00
0.00
5.17
-1.18
0.92
0.08
-1.87
-1.99
Others
11.79
-3.98
-4.20
-4.28
-12.93
0.48
-3.80
-0.05
1.92
1.52
Cash from Financing Activity
7.04
-14.44
-17.40
0.99
5.66
0.77
11.77
-2.00
5.39
4.60
Net Cash Inflow / Outflow
-11.28
9.76
-0.81
-6.07
3.33
4.27
0.14
-0.21
-1.38
1.65
Opening Cash & Equivalents
12.02
2.26
3.07
9.13
5.81
1.54
1.40
1.61
2.99
1.35
Closing Cash & Equivalent
0.74
12.02
2.26
3.07
9.13
5.81
1.54
1.40
1.61
2.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
318.80
253.70
215.31
192.48
173.81
58.16
43.57
35.14
27.83
23.79
ROA
13.01%
9.48%
6.32%
5.55%
47.33%
9.97%
6.90%
7.50%
5.29%
5.37%
ROE
22.67%
16.36%
11.16%
10.15%
99.66%
28.21%
20.10%
23.13%
16.51%
14.41%
ROCE
24.01%
18.36%
13.57%
12.27%
95.32%
26.36%
18.49%
21.91%
19.19%
19.74%
Fixed Asset Turnover
2.04
1.69
1.63
1.68
4.34
3.62
2.53
3.98
4.20
3.76
Receivable days
157.57
132.46
110.56
102.38
41.94
46.00
90.08
82.82
79.17
75.44
Inventory Days
58.67
79.79
97.85
101.54
28.29
27.71
44.10
28.84
38.34
44.92
Payable days
160.16
157.23
161.90
183.20
78.14
54.20
56.97
49.86
49.48
45.68
Cash Conversion Cycle
56.07
55.02
46.51
20.73
-7.91
19.51
77.22
61.80
68.03
74.67
Total Debt/Equity
0.39
0.43
0.44
0.45
0.35
0.68
0.77
0.79
0.92
0.77
Interest Cover
9.16
6.48
3.99
4.87
56.38
8.93
5.32
5.76
4.31
3.89

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Kwality Pharma - Quarterly Results
    11th Aug 2026, 00:00 AM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.